Linze Li

Linze Li

Auto-generated profile, based on publicly available information

Linze Li

The Operation Room, The Fourth Affiliated Hospital of China Medical University, Shenyang, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
LLLi Liu
Li Liu
ZHZhanying Hao
Zhanying Hao
XYXi Yang
Xi Yang
YLYan Li
Yan Li
SWSiyang Wang
Siyang Wang
LLLinze Li
Linze Li
The complex interplay between cancer progression and immune senescence is critically influenced by metabolic reprogramming in T cells. As T cells age, especially within the tumor microenvironment, they undergo significant metabolic shifts that may hinder their proliferation and functionality. This manuscript reviews how metabolic alterations contribute to T cell senescence in cancer and discusses potential therapeutic strategies aimed at reversing these metabolic changes. We explore interventions such as mitochondrial enhancement, glycolytic inhibition, and lipid metabolism adjustments that could rejuvenate senescent T cells, potentially restoring their efficacy in tumor suppression. This review also focuses on the significance of metabolic interventions in T cells with aging and further explores the future direction of the metabolism-based cancer immunotherapy in senescent T cells.

4 December 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MHMingyao Huang
Mingyao Huang
SWSiyang Wang
Siyang Wang
HHHuiyan Huang
Huiyan Huang
LLLinze Li
Linze Li
TWTian Wang
Tian Wang
Gynecological malignancies, including ovarian, cervical, and endometrial cancers, represent a substantial global health burden, contributing significantly to morbidity and mortality among women. Despite advancements in therapeutic strategies, outcomes for many patients remain suboptimal due to challenges such as late-stage detection and resistance to standard treatments. The advent of chimeric antigen receptor (CAR)-engineered natural killer (NK) cells has introduced a cutting-edge immunotherapy option. This review provides an in-depth exploration of the development of CAR-NK cells, emphasizing their sources, design methodologies, and applications in managing gynecological cancers. It also examines current obstacles and outlines innovative strategies to improve the effectiveness and safety of CAR-NK cell-based therapies. Furthermore, we discuss prospective advancements, highlighting the importance of ongoing research and technological innovation to unlock the full potential of CAR-NK cells in the fight against gynecological cancers.